You are here
- Home
- Interstitial Fibrosis
Interstitial Fibrosis
- Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trialsLisa Lancaster, Bruno Crestani, Paul Hernandez, Yoshikazu Inoue, Daniel Wachtlin, Lazaro Loaiza, Manuel Quaresma, Susanne Stowasser, Luca RicheldiBMJ Open Respiratory Research Mar 2019, 6 (1) e000397; DOI: 10.1136/bmjresp-2018-000397
- Specialist palliative care, psychology, interstitial lung disease (ILD) multidisciplinary team meeting: a novel model to address palliative care needsShaney L Barratt, Michelle Morales, Toby Spiers, Khaled Al Jboor, Heather Lamb, Sarah Mulholland, Adrienne Edwards, Rachel Gunary, Patricia Meek, Nikki Jordan, Charles Sharp, Clare Kendall, Huzaifa I AdamaliBMJ Open Respiratory Research Dec 2018, 5 (1) e000360; DOI: 10.1136/bmjresp-2018-000360
- Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registryWim A Wuyts, Caroline Dahlqvist, Hans Slabbynck, Marc Schlesser, Natacha Gusbin, Christophe Compere, Sofie Maddens, Klaus-Uwe Kirchgaessler, Karen Bartley, Benjamin BondueBMJ Open Respiratory Research Nov 2018, 5 (1) e000331; DOI: 10.1136/bmjresp-2018-000331
- Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK®trialToby M Maher, Susanne Stowasser, Yasuhiko Nishioka, Eric S White, Vincent Cottin, Imre Noth, Moisés Selman, Zuzana Blahova, Daniel Wachtlin, Claudia Diefenbach, R Gisli JenkinsBMJ Open Respiratory Research Aug 2018, 5 (1) e000325; DOI: 10.1136/bmjresp-2018-000325
- Dose modification and dose intensity during treatment with pirfenidone: analysis of pooled data from three multinational phase III trialsSteven D Nathan, Lisa H Lancaster, Carlo Albera, Marilyn K Glassberg, Jeffrey J Swigris, Frank Gilberg, Klaus-Uwe Kirchgaessler, Susan L Limb, Ute Petzinger, Paul W NobleBMJ Open Respiratory Research Aug 2018, 5 (1) e000323; DOI: 10.1136/bmjresp-2018-000323
- Transitions and touchpoints in idiopathic pulmonary fibrosisJeffrey J SwigrisBMJ Open Respiratory Research Jun 2018, 5 (1) e000317; DOI: 10.1136/bmjresp-2018-000317
- Psychometric properties of the St George’s Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis: insights from the INPULSIS trialsJeffrey J Swigris, Hilary Wilson, Dirk Esser, Craig S Conoscenti, Wibke Stansen, Nancy Kline Leidy, Kevin K BrownBMJ Open Respiratory Research May 2018, 5 (1) e000278; DOI: 10.1136/bmjresp-2018-000278
- Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung diseaseKevin R Flaherty, Kevin K Brown, Athol U Wells, Emmanuelle Clerisme-Beaty, Harold R Collard, Vincent Cottin, Anand Devaraj, Yoshikazu Inoue, Florence Le Maulf, Luca Richeldi, Hendrik Schmidt, Simon Walsh, William Mezzanotte, Rozsa Schlenker-HercegBMJ Open Respiratory Research Sep 2017, 4 (1) e000212; DOI: 10.1136/bmjresp-2017-000212
- Singing for Lung Health: a qualitative assessment of a British Lung Foundation programme for group leadersAdam Lewis, Phoene Cave, Nicholas S HopkinsonBMJ Open Respiratory Research Jul 2017, 4 (1) e000216; DOI: 10.1136/bmjresp-2017-000216
- Clinical use of nintedanib in patients with idiopathic pulmonary fibrosisAmy Hajari Case, Peace JohnsonBMJ Open Respiratory Research Jun 2017, 4 (1) e000192; DOI: 10.1136/bmjresp-2017-000192
Pages
- BMJ Open Respiratory Research
- Cough (3)
- Critical care (8)
- Cystic fibrosis (3)
- Lung cancer (9)
- Sleep (2)
- Thoracic surgery (1)
- Tuberculosis (2)